Target | Role | Current Status | Concerns |
---|---|---|---|
Somatostatin | Neuroprotective, antiangiogenic. Downregulated in retinas of diabetics, associated with retinal neurodegeneration [54]. | Recently completed multi-center phase II-III trial (EUROCONDOR) to assess the safety of topically administered somatostatin. (EudraCT Number: 2012–001200-38) Results have yet to be published. |  |
Glucagon-like peptide (GLP-1) | Neuroprotective [55] | Intravitreal injections of exedin-4 (a GLP-1 analogue) prevent ERG abnormalities in rats with streptozotoin-induced diabetes [56]. Topical administration of GLP-1R agonists prevents retinal neurodegeneration in mice with diabetes [57]. | 2 large clinical trials of GLP-1 analogues in type 2 diabetics with high cardiovascular risk (LEADER and SUSTAIN-6) have shown neutral benefit [58] or even worsening of DR compared to placebo [59]. However, these studies were not designed to assess progression of DR. |
Doxycycline | Anti-inflammatory and neuroprotective [60] | Low-dose oral doxycycline improves inner retinal function in DR compared to placebo [61]. | Although statistical significance was achieved at multiple time points, it was a small, proof-of-concept trial. |
Interleukin 1β (IL-1β) | Inflammatory cytokine | Systemic IL-1β inhibition has been shown to stabilize retinal neovascular changes in proliferative DR and reduce macular edema [62]. | Open-label, small, prospective pilot study. Reduction in macular edema was not statistically significant. |
Tumor necrosis factor α (TNF-α) | Inflammatory, induces vascular changes | Intravitreal injection of TNF-α inhibitor decreased capillary degeneration in diabetic rats [63]. | Very small study in rats, with other primary endpoints. |